Gene edit­ing com­pa­ny Metageno­mi sub­mits IPO pa­per­work in third planned biotech list­ing of 2024

Metageno­mi sub­mit­ted its plans for an ini­tial pub­lic of­fer­ing on Fri­day night, in what would be one of the on­ly pre­clin­i­cal gene edit­ing biotechs to IPO in the past two years as in­vestors have cooled on the cat­e­go­ry.

The biotech ex­pects to list on the Nas­daq as $MGX, af­ter rais­ing more than $400 mil­lion in pri­vate cap­i­tal. Its biggest cur­rent eq­ui­ty hold­ers in­clude Bay­er, Hum­boldt Fund, Mod­er­na, Sake Hold­ings, So­zo Ven­tures and RA Cap­i­tal, ac­cord­ing to a se­cu­ri­ties fil­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER